Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial

Monique C. Minnema*, Kazem Nasserinejad, Bouke Hazenberg, Ute Hegenbart, Philip Vlummens, Paula F. Ypma, Nicolaus Kroeger, Ka Lung Wu, Marie Jose Kersten, M. Ron Schaafsma, Sandra Croockewit, Esther de Waal, Sonja Zweegman, Lidwien Tick, Annemieke Broijl, Harry Koene, Gerard Bos, Pieter Sonneveld, Stefan Schoenland

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2274-2282
Number of pages9
JournalHaematologica-the Hematology Journal
Volume104
Issue number11
DOIs
Publication statusPublished - 30 Oct 2019

Keywords

  • HIGH-DOSE MELPHALAN
  • SYSTEMIC AL AMYLOIDOSIS
  • HEMATOLOGIC RESPONSE
  • CARDIAC BIOMARKERS
  • STAGING SYSTEM
  • DEXAMETHASONE
  • THERAPY
  • BLOOD
  • CYCLOPHOSPHAMIDE
  • PROGRESSION

Cite this